Welcome to the Q3 2023 edition of Global Health & Pharma magazine, providing you with all the latest news and features from across the healthcare and pharmaceutical landscape. Q3 2023 So far, 2023 has been an incredibly prosperous year for the health and pharma industry. As always, we’re delighted to be showcasing some the extraordinary organisations who are making this the case, with our award winners including the best of the best. Take a look through these pages to explore the most innovative and dedicated companies, whether they specialise in Point of Care Testing, clinical trial solutions, pharmaceutical clinical research, laser skin health, infection prevention solutions, and more. On our front cover we feature ICROM, our Best Active Pharmaceutical Ingredients Manufacturer 2023 – Italy, led by CEO, Pierfrancesco Morosini. We gain an exciting insight into the company’s chemicalpharmaceutical manufacturing services and its devotion to providing only the highest of standards for its customers and their patients. ICROM boasts five decades of experience, with a team whose extensive know-how enables them to build high-tech solutions to create complex molecules. I hope you enjoy perusing this issue and find each of our award-winning business’ stories to be inspirational and insightful. All of us at GHP wish you a wonderful quarter ahead and look forward to welcoming you back again in Q4. Rebecca Scotland, Editor Website: www.ghp-news.com AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.